TIDES-OCT: Randomised multicenter trial comparing Optimax titanium-nitride-oxide coated stent versus Promus-Element stent Tuomas Kiviniemi, MD, PhD Turku.

Slides:



Advertisements
Similar presentations
Pooled Analysis of Trials Comparing Titanium Nitride Oxide Coated Stents with Paclitaxel Eluting Stents in Patients Undergoing PCI Otto M. Hess Swiss Cardiovascular.
Advertisements

Introduction Recent guidelines considered PCI to be a potential alternative to CABG for ULMCA stenosis, based on several large registries and randomized.
A PROSPECTIVE MULTICENTRE REGISTRY FOR THE ASSESSMENT OF SAFETY AND EFFICACY OF BIODEGRADABLE POLYMER COATED, PACLITAXEL ELUTING STENT LUC TM * *(BALTON,
Five-Year Follow-up of Safety and Efficacy of the Resolute Zotarolimus-Eluting Stent: Insights from the RESOLUTE Global Clinical Trial Program in Approximately.
2 Year Clinical Outcomes from the Pivotal RESOLUTE US Study Laura Mauri MD, MSc on behalf of the RESOLUTE US Investigators Brigham and Women’s Hospital.
Clinical Result Overview
As presented by Patrick W. Serruys, MD, PhD, FACC Principal Investigator Thoraxcentre - Erasmus University Rotterdam, The Netherlands PISCES Paclitaxel.
BIOSENSORS-CLINICAL UPDATE “LEADERS AND BEYOND” John E Shulze, CTO BIOSENSORS INTERNATIONAL GROUP Jan 29, 2010.
TITAX AMI Trial Y. Giraud-Sauveur on behalf of P.Karjalainen, MD, PhD : Principal Investigator BCIS 2009 London, UK A Prospective, Randomized Trial Comparing.
Clinical Trial Results. org Evaluation by Optical Coherence Tomography (OCT) of Neointimal Coverage of Sirolimus-Eluting Stent Three Months After Implantation.
For OMA distribution only. Trademarks may be registered and are the property of their respective owners © 2015 Medtronic, Inc. All Rights Reserved DOC_1A.
AICT 2010-Athens Interventional Cardiovascular Therapeutics XI 8-9 OCTOBER 2010 Divani Caravel Hotel, Αthens EARLY CLINICAL OUTCOMES AFTER PROMUS ELEMENT.
OCT Assessment of Late Stent Malapposition after DES
A Prospective, Randomized Trial Evaluating a Paclitaxel-Eluting Balloon in Patients TReated with Endothelial Progenitor Cell CapTuring Stents for De Novo.
Clinical Experience with the Bio Active Stent (BAS) in FINLAND 9 e CFCI Hotel Meridien Etoile Paris, France 10 Octobre 2007 Pasi Karjalainen, MD, PhD.
The stented vessel wall Dr Miles Dalby Consultant Cardiologist Royal Brompton Hospital Harefield Hospital Senior Lecturer Imperial College.
The MASTER Trial A Prospective, Randomized, Multicenter Evaluation of a PET Micronet Mesh Covered Stent (MGuard) in STEMI Sigmund Silber, MD, PhD FESC,
Drug Eluting Balloon in Acute Myocardial Infarction: (PI) On behalf of the DEB-AMI study group (PI) P.R. Stella, MD, PhD 6 month.
SONG XIANTAO MD Beijing Anzhen Hospital affiliated to Capital Medical University.
Early and Late Stent Thrombosis Rates in 5,054 Real-World Patients from XIENCE V USA With and Without Dual Antiplatelet Therapy Interruptions James Hermiller,
Results From the MISSION! Intervention Study Sirolimus-Eluting Stents Vs Bare-Metal Stents in Patients With STEMI : 9-Month Angiographic and Intravascular.
Philippe Généreux, MD for the Tryton Bifurcation Trial Investigators Columbia University Medical Center Cardiovascular Research Foundation New York City.
Real-world clinical experience with an everolimus eluting platinum chromium stent with an abluminal biodegradable polymer – a report from the Swedish Coronary.
Durable Polymer DES: 5 Year Outcomes RESOLUTE Update Sigmund Silber, MD FESC, FACC, FAHA Heart Center at the Isar Munich, Germany On Behalf of the RESOLUTE.
Prof. Dr. Sigmund Silber, FESC, FACC On behalf of the RESOLUTE
on behalf of the Investigators
Background & Study Design
Use of OCT in Determining Dual Antiplatelet Treatment Duration
The OPTIMAX first-in-man study Mid-term clinical outcome of Titanium-Nitride-Oxide-coated Cobalt Chromium stents in patients with de novo coronary artery.
Everolimus-eluting Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Disease: ABSORB III Trial 2-Year Results Stephen G. Ellis, MD,
Ospedale San Raffaele, Milan, Italy
My initial ABSORB experience Assoc. Prof. I. Petrov
Latvian Centre of Cardiology real-life registry
Invasive Assessment of Coronary Artery Disease
New Generation Resolute Integrity Drug-Eluting Stent Superior to Benchmark Xience Drug-Eluting Stent: Primary Endpoint Results from the PROPEL Study –
Three-year results from the multicentre PROMUS Element European Post-Approval (PE-Prove) Registry: outcomes in 1010 unselected patients treated with a.
RevElution Clinical Trial
OCT and Stent Thrombosis
Main Arena IV - Plenary Session XXVII: First Reports #4
12 Month Outcomes in Patients with Diabetes Mellitus Implanted with a Resolute Zotarolimus-eluting Stent: Initial Results from the RESOLUTE Global Clinical.
Harmonized Assessment by Randomized Multicenter Study of OrbusNEich’s COMBO StEnt Japan-USA HARMONEE: Primary Report of A Randomized Trial of a Bioabsorbable.
Did the LEADERS trial prove the superiority of biodegradable polymer?
BVS Expand: First Results of Wide Clinical Applications
Prof. Stephen G. Worthley
Stent Thrombosis Rates in Contemporary Clinical Practice: Insight from a Large Australian Multi-centre Registry BP Yan*, TJ Kiernan, SJ Duffy, DJ Clark,
The RESOLUTE Program: today and tomorrow
On behalf of J. Belardi, M. Leon, L. Mauri,
William Wijns MD PhD Thomas Cuisset MD
Early strut coverage in patients receiving new-generation drug-eluting stents and its implications for dual antiplatelet therapy: a randomized clinical.
Glenn N. Levine et al. JACC 2016;68:
Bern-Rotterdam Registry Published in the Lancet
How and why this study may change my practice ?
Kyoto University Hospital, Japan
3-Year Clinical Outcomes From the RESOLUTE US Study
Efficacy of Xience/Promus versus Cypher to rEduce Late Loss in stENT
TRIAL HIGHLIGHT FROM ESC 2016: ACUTE CORONARY SYNDROMES
Large-Scale Registry Examining Safety and Effectiveness of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease Western.
Impact of Platelet Reactivity Following Clopidogrel Administration
STENT THROMBISIS Insights on Outcomes and Impact of DUAL ANTIPLATELET THERAPY Permanent Discontinuation SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE.
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
On behalf of all principal COMPARE II investigators:
for the SPIRIT IV Investigators
Figure 5 Bioresorbable vascular scaffold apposition and strut coverage
FOR DISTRIBUTION BY MEDTRONIC OFFICE OF MEDICAL AFFAIRS ONLY.
John A. Bittl et al. JACC 2016;68:
Martin B. Leon, David R. Holmes, Dean J. Kereiakes, Jeffrey J
Maintenance of Long-Term Clinical Benefit with
Angioplasty Balloon-associated Coronary Debris and the EZ FilterWire
Comparison of Everolimus-Eluting and Paclitaxel-Eluting Stents: First Report of the Five-Year Clinical Outcomes from.
Presentation transcript:

TIDES-OCT: Randomised multicenter trial comparing Optimax titanium-nitride-oxide coated stent versus Promus-Element stent Tuomas Kiviniemi, MD, PhD Turku University Hospital Finland

Potential conflicts of interest Speaker's name: Tuomas Kiviniemi  I have the following potential conflicts of interest to report: Institutional grant/research support: ASTRAZENECA

Background Rapid vascular healing after PCI could enable shorter dual antiplatelet therapy in patients at high risk for bleeding complications

Background Recent data suggests a paradigm shift in the occurrence of stent thrombosis (ST) – Rate of early and late ST in PtCr- EES < BMS – Uncovered struts and chronic inflammation identified as a nidus for thrombosis Palmerini et al, Lancet 2012

Stent thrombosis with BAS? BASE-ACS, EuroIntervention 2012

New Co-Cr Alloy Platform Optimax ’’ Stainless Steel Stent Platform Cobalt Chromium Stent Platform  20% THINNER STRUTS (75 microns) Stefanini G G et al. Heart doi: /heartjnl BVS Optimax

TIDES-OCT study 40 Patients with Acute coronary syndrome (ACS) Randomisation 1:1 OCT and CFR/FFR at 2 months OPTIMAX-BAS Titanium-Nitride-Oxide coated Bio Active Stent (n = 21) PROMUS-Element-EES Everolimus Eluting Stent (n = 19) Academic, investigator driven trial in 4 Finnish PCI centers

Optical Coherence Tomography (OCT) OCT C7xr TM (St.Jude Medical) OCT Examination - C7xr Cardiology Imaging System (LightLab Imaging inc, Westford, MA, USA) - A motorized pull-back system at 20 mm/s was used  54.0 mm / 2.7 sec - 6 Fr guiding catheter - During image acquisition, contrast media was infused at 3-6 ml/s - Images were stored digitally for subsequent analysis

1. Neointimal hyperplasia (NIH) thickness, µm - Distance between the vessel wall to the endo-luminal surface of the strut - NIH thickness inside every strut was measured Strut Level Analysis: Cross-sectional OCT images were analyzed at 1-mm interval (every 5 frames) 2. Binary Strut Coverage (%) Number of strut sections covered Total number of strut sections examined x 100 OCT Analysis

3. Apposition (%) A) Apposed and covered B) Apposed and uncovered C) Malapposed and covered D) Malapposed and uncovered E) Strut within the side branch

OCT Analysis 3. Apposition (%) A) Apposed and covered B) Apposed and uncovered C) Malapposed and covered D) Malapposed and uncovered E) Strut within the side branch

Coronary flow reserve Rationale: - The cutpoint value for normal CFR is 2.0 If CFR is < 2.0 -with no epicardial stenosis or ISR -IMR normal and no diabetes (microvascular dysfunction)  Endothelial dysfunction?  Delayed vascular healing after stenting? We sought to examine vascular healing after OPTIMAX- BAS and PROMUS-Element-EES implantation with combining data from OCT and CFR measurements

Invasive CFR, FFR and IMR Thermodilution-derived CFR I.v. adenosine infusion * Invasive measurements were performed using PressureWire Certus in the index vessel. * Thermodilution-derived CFR and IMR measurements were carried on during adenosine infusion

Baseline Demographics Optimax* (n=19) Promus-Element (n=19) P value Age (years)59 ± 968 ± Male74 %58 %0.50 Diabetes5 %16 %0.60 Hyperlipidemia58 %84 %0.15 Hypertension63 %84 %0.27 Current smoker37 %21 %0.48 Prior myocardial infarction11 %21 %0.66 Prior PCI16 %21 %1.0 Prior CABG0 %5 %1.0 NSTEMI42 %58 %0.30 STEMI47 %21 %0.21 * 2/21 patients had OCT follow-up later than 5 months after index PCI and were excluded from the analysis

OPTIMAX (n=19pts) PROMUS-Element (n=19pts) P value LAD58 % 1.0 Reference vessel diameter (mm)3.12 ± ± Lesion length (mm)14.0 ± ± Stent diameter (mm)3.33 ± ± Stent length (mm)17.4 ± ± Thrombus aspiration21 %11 %0.66 Post-Dilatation58 %63 %1.0 Stent failure0 % 1.0 Procedural Characteristics

Follow-Up Measurement TIDES-OCT at 2 months Follow-Up Measurement OPTIMAX 19 pts PROMUS-Element P No. of Cross Sections No. of Cross Sections No. of Struts No. of Struts Struts per cross section Struts per cross section 11.3 ± ± Mean NIH Thickness (µm)* 240 ± ± 59.5 < Binary Strut Coverage (%)*98.1%85.3% < Presence of Thrombi n (%) Presence of Thrombi n (%) 0 (0) --- * Stent level analysis

p < % 625 cross-sections / 6872 struts Follow-Up Measurement TIDES-OCT at 2 months Follow-Up Measurement OPTIMAX vs. PROMUS-Element Cross sections with uncovered struts: 8.6% vs. 54.0% (p<0.001) Cross sections with malapposed struts: 3.7% vs. 9.3% (p<0.001)

Uncovered struts with DES 2-3 months % 3.9% - 14% 4.7% - 9% 6.2% - 8.9% * REMEDEE-OCT trial ^ Hatrick-OCT trial ” Kim et al.

Coronary vasodilator function Delayed vascular Healing? Coronary Flow Reserve (CFR)

Take home message Newer generation BAS shows good coverage and functional healing response at 2 months FU